Treatment of cancer-related thrombosis: from recommendations to real clinical practice
- Authors: Somonova O.V1, Elizarova A.L1, Blindar V.N1, Dobrovolskaya M.B1, Nesterova Y.A1, Borisenko N.N1, Kornyushenko U.A1, Davidova T.V1
-
Affiliations:
- N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
- Issue: Vol 21, No 1 (2019)
- Pages: 60-65
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/33533
- DOI: https://doi.org/10.26442/18151434.2019.1.190247
- ID: 33533
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Oksana V Somonova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: somonova@mail.ru
MD, Ph.D., Leading Researcher 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Anna L Elizarova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationCand. Sci. (Biol.), Senior Researcher 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Valentina N Blindar
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationPh.D biology, Leading Researcher 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Marina B Dobrovolskaya
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationCand. Sci. (Biol.), Researcher 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Yulia A Nesterova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationResearch Assistant 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Natalia N Borisenko
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationResearcher 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Ustin A Kornyushenko
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationResearch Assistant 24, Kashirskoe sh., Moscow, 115478, Russian Federation
Tatiana V Davidova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationHead of Clinical Laboratory Diagnostics 24, Kashirskoe sh., Moscow, 115478, Russian Federation
References
- Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost 2011; 9 (Suppl. 1): 316-24. doi: 10.1111/j.1538-7836.2011.04346.x
- Barsam S.J, Patel R, Arya. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. Br J Haematol 2013; 161 (Iss. 6): 764-77. doi: 10.1111/bjh.12314
- Wun T, White R.H. Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haemotol 2009; 22 (1): 9-23. DOI: 0.1016/j.beha.2008.12.001
- Shaib W, Deng Y, Zilterman D et al. Assessing risk and mortality of venous thromboembolism in pancreatic cancer patients. Anticancer Res 2010; 30 (10): 4261-4.
- Kakkar A.K, Haas S, Walsh D et al. Prevention of perioperative venous thromboembolism: outcome after cancer and non-cancer surgery (abstract). Thromb Haemost 2001; 86 (Suppl.): 0c1732. doi: 10.5144/0256-4947.2015.95
- Ogren M, Bergqvist D, Wahlander K et al. Trousseaus syndrome - what is the evidence? A population - based autopsy study. Thromb Haemost 2006; 95: 541-5. doi: 10.1160/TH05-10-0694
- Liebman H.A. Cancer prognosis in patients with venous thromboembolism (VTE) and patients with clinical and laboratory biomarkers predictive of VTE risk. Thromb Res; 2018; 164 (Suppl. 1): S19-22. doi: 10.1016/j.thromres.2018.01.040.
- Sorensen H.T, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50. doi: 10.1056/NEJM200012213432504
- Robin P, Carrier M. Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. Thromb Res 2018; 164 (Suppl. 1); S7-S11. doi: 10.1016/j.thromres.2017.12.024
- Magnus N, D’Asti E, Meehan B et al. Oncogenes and the coagulation system - forses that modulate dormant and aggressive states in cancer. Thromb Res 2014; 133 (Suppl. 2): S1-S9. https://doi.org/ 10.1016/S0049-3848(14)50001-1
- Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thromb Res 2018; 164 (Suppl. 1): S54-S61. doi: 10.1016/j.thromres.2018.01.017
- Cedervall J, Hamidi A, Olsson A-K. Platelets, NETs and cancer. Thromb Res 2018; 164 (Suppl. 1): S48-S52. doi: 10.1016/j.thromres.2018.01.049
- Nazari P.M.S, Riedy J, Pabinger I, Cihan Ay. The role of pododlanin in cancer-associated thrombosis. Thromb Res 2018; 164 (Suppl. 1): S34-S39. doi: 10.1016/j.thromres.2018.01.020
- Ten C.H, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb 2007; 36: 122-30. doi: 10.1159/000175150
- Agnelii G, Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thromb Res 2010; 125 (Suppl. 2): S17-S20. doi: 10.1016/S0049-3848(10)70007-4
- Сомонова О.В. Диагностика нарушений гемостаза и принципы их коррекции при тромботических осложнениях в онкологии. Дис. … д-ра мед. наук. М., 2008.
- Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015; 9 (4; Вып. 2): 2-52.
- Franchini M, Bonfanti C, Lippi G. Cancer-associated thrombosis: investigating the role of new oral anticoagulants. Thromb Res 2015; 135 (5): 777-81. doi: 10.1016/j.thromres.2015.02.024
- Mandala M, Tondini C. Adjuvant therapy in breast cancer and venous thromboembolism. Thromb Res 2012; 130: S66-S70. doi: 10.1634/theoncologist.2012-0261
- Levine M.N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997; 78: 133-6.
- Goodnough L, Saito A, Manni A. Increased incidence of thromboembolism in stage IV breast cancer patients treated with five-drug chemotherapy regimen: a study of 150 patients. Cancer 1984; 78: 133-6. doi: 10.4061/2011/394740
- Otten H.M, Mathijssen J, Ten CH et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Inter Med 2004; 164: P190-4. doi: 10.1001/archinte.164.2.190
- Kearon C, Akl E.A, Ornelas J et al. Antithrombotic therapy for VTE disease. Chest 2016; 149 (2): 315-52. doi: 10.1016/j.chest.2 015.11.026
- Watson H.G, Keeling D.M, Laffan M et al. On behalf of British Committee for Standarts in Haemotology. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol 2015; 170 (Issue 5): 640-8. doi: 10.1111/bjh.13556
- Lee A.Y, Levine M.N, Baker M.D et al. Low-Molecular-Weight Heparin versus a Coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53. doi: 10.1056/NEJMoa025313
- Piran S, Schulman S. Management of recurrent venous thromboembolism in patients with cancer: a review. Thromb Res 2018; 164 (Suppl. 1): S172-S177. doi: 10.1016/j.thromres.2017.12.019
- Khorana A., Yannicelli D, McGrae K.R et al. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res 2016; 14: 51-3. doi: 10.1016/j.thromres.2016.07.013
- Weitz J еt al. Clinical characteristics and initial treatment of patients with CAT. Results from Garfield VTE registry. Poster PB 460 presented at ISTH 2017.
- Prints M.H, Lensing A.W, Bauersachs R et al. Oral rivaroxaban versus standart therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21-31. https://doi.org/ 10.1186/1477-9560-11-21
- Prints M.H, Lensing A.W.A, Brighton T.A et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomized controlled trials. Lancet Haematol 2014; 1: e37-e46. doi: 10.1016/S2352-3026(14)70018-3
- Büller H.R, Prins M.H, Lensin A.W et al. Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97. DOI: 0.1056/NEJMoa1113572
- Van der Hulle T, den Exter P.L, Kooiman J et al. Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J Thromb Haemost 2014; 12 (7): 1116-20. doi: 10.1111/jth.12605
- Khorana A.A, McCrae K, MilentiJevic D et al. VTE recurrence and safety of anticoagulants among patients with cancer treated for venous thromboembolism. Blood 2017; 130: 4631.
- McBane R.D et al. presented at ACC 2016, abstract 1243M-05. doi: 10.7899/JCE-13-14
- Khorana A.A et al. presented at ASH 2017, abstract 4631.
- Ageno W, Mantovany L.G, Haas S et al. Subgroup analysis of patients with cancer in XALIA: a noninterventional study of rivaroxaban versus standard anticoagulation for VTE. TH Open 2017; 1 (1e): e33-e42. https://doi.org/.10.1055/s-0037-1603924
- Young A.M, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SEL ECT-D). J Clin Oncol 2018; 36 (20): 2017-23. doi: 10.1200/JCO.2018.78.8034
- Khorana A.A, Noble S, Lee A.Y et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance fr om the SSC of the ISTH. J Thromb Haemost 2018; 16: 1891-4. doi: 10.1111/jth.14219
- Streiff M.B, Holmstron B, Angelini D et al. NCCN Guidelines Insights. Cancer-associated venous thromboembolic disease, version 2.2018. Featured updates to the NCCN Guidelines. J. of the National Comprehensive cancer network. 2018; 16(11): 1289-303. doi: 10.6004/jnccn.2018.0084